SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following initial in-vitro results. MitoCareX recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatments. By leveraging its in-vitro screening systems related to mitochondria, MitoCareX corroborated the anti-cancer biological activity of several small molecule structures discovered out of millions of them that were virtually screened the addition of pancreatic cancer to its existing focus on non-small cell lung cancer marks a significant expansion of its therapeutic ambitions.